Use of infliximab in the treatment of Crohn's disease in children and adolescents

Journal of Pediatric Gastroenterology and Nutrition

Volumn 33, Issue SUPPL. 1, 2001, Pages

  Hyams, J S ^a  

^a Farmington   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INFLIXIMAB;

ADOLESCENT; ADULT; CHILDHOOD DISEASE; CLINICAL FEATURE; CONFERENCE PAPER; CROHN DISEASE; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DYSPNEA; ERYTHEMA; HUMAN; PRIORITY JOURNAL; SCHOOL CHILD; SCORING SYSTEM;

EID: 0034790872     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005176-200109001-00006     Document Type: Conference Paper

References (18)

1. Prognosis in children with Crohn's disease
2. Inflammatory bowel disease in pediatric and adolescent patients
3. Growth and clinical course of children with Crohn's disease
4. Inflammatory bowel diseases with onset in childhood. Clinical features, morbidity, and mortality in a regional cohort
5. Crohn's disease: Influence of age at diagnosis on site and clinical type of disease
6. Long term prognosis of Crohn's disease with onset in childhood and adolescence
7. Epidemiology and the natural course of inflammatory bowel disease
8. Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease
9. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor a for Crohn's disease
10. Infliximab for Crohn's disease in clinical practice at the Mayo Clinic: The first 100 patients
11. Efficacy and safety of retreatment with anti-tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease
12. A multicenter study of infliximab (anti-TNFα antibody) in the treatment of children with active Crohn's disease
13. Treatment of pediatric Crohn's disease (CD) with anti-tumor necrosis factor alpha chimeric monoclonal antibody (infliximab)
14. Collaborative experience of open-label anti-TNF alpha chimeric monoclonal antibody, Remicade, in pediatric patients with refractory Crohn's disease
15. Use of infliximab in the treatment of Crohn's disease in children and adolescents
16. Prolonged duration of response to infliximab in early but not late pediatric Crohn's disease
17. Long term safety of infliximab
18. Review article: Safety of infliximab in clinical trials